Get the Stockscreener App
38.83
0.99%
-0.39
Novo Nordisk Adr stock is traded at $38.83, with a volume of 9.46M.
It is down -0.99% in the last 24 hours and down -6.90% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$39.22
Open:
$39.33
24h Volume:
9.46M
Relative Volume:
0.79
Market Cap:
$171.36B
Revenue:
$50.91B
Net Income/Loss:
$18.95B
P/E Ratio:
9.1129
EPS:
4.261
Net Cash Flow:
$1.92B
1W Performance:
+0.49%
1M Performance:
-6.90%
6M Performance:
-5.13%
1Y Performance:
-30.77%
1-Day Range:
$38.67
$39.40
1-Week Range:
$37.90
$39.68
52-Week Range:
$35.12
$64.16
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
38.83 | 171.36B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,257.03 | 1.12T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.56 | 615.87B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.42 | 504.37B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.95 | 360.08B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.62 | 286.29B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-26 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-27-26 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-12-26 | Downgrade | Berenberg | Buy → Hold |
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-18-26 | Initiated | Bernstein | Outperform |
| Mar-10-26 | Downgrade | TD Cowen | Buy → Hold |
| Mar-03-26 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-02-26 | Downgrade | Goldman | Buy → Neutral |
| Feb-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-24-26 | Downgrade | Kepler | Buy → Hold |
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-12-26 | Upgrade | Jefferies | Underperform → Hold |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Novo Nordisk A/S Tokenized Stock (Coinbase) Price Today - CryptoRank
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
Novo Nordisk A/S : UBS remains Neutral - marketscreener.com
Novo Nordisk (NVO) Could Be 63% Undervalued Following Its Share Buyback - Yahoo Finance
Roche Expands Obesity Pipeline With Rona's RNAi Candidate - Zacks Investment Research
Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now? - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum - Zacks Investment Research
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Zacks Investment Research
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Yahoo Finance
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Zacks Investment Research
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Yahoo Finance
Novo Nordisk A/S: Dividend historical data and projections - marketscreener.com
GLP-1 weight-loss drugs slow biological aging, recent studies show - NewsNation
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme - TipRanks
Buybacks total 37.8M B shares at Novo Nordisk (NVO), under a programme capped at DKK 15B. - Stock Titan
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. - The Motley Fool
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
4 Healthcare Stocks Worth Owning for the Next Decade - The Motley Fool
Novo Nordisk price target lowered to $40 from $47 at BMO Capital - TipRanks
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $40 - Moomoo
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - Zacks Investment Research
Novo Nordisk A/Sshare repurchase programme - The Manila Times
Novo Nordisk A/Sshare repurchase programme - GlobeNewswire
Novo Nordisk A/Sshare repurchase programme - Yahoo Finance
Novo Nordisk A/S (NVO) Stock Forecast and Price Target 2026 $NVO - MarketBeat
Weekly Recap: Large B-share buyback and GLOBE pricing deal participation - TradingView
Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh Actuals & Estimates (SET:NOVOB80) - TradingView
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? - The Motley Fool
As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze - The Motley Fool
Novo Nordisk A/S (NVO) Options Chain - Yahoo! Finance Canada
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Globe and Mail
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth - Yahoo Finance
Novo Nordisk loses another patent behind Ozempic and Wegovy drugs - JUVE Patent
Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data Land - Yahoo Finance
Novo Nordisk A/S (NVO) Stock Forecasts - Yahoo Finance
Novo Nordisk stock target cut at Citi on lack of margin growth - Yahoo Finance
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. - The Motley Fool
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. - The Motley Fool
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Novo Nordisk A/S (NOV.DU) recent insider transactions - Yahoo Finance UK
Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’ - Barchart.com
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response - Yahoo Finance
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium (NYSE:NVO) - Seeking Alpha
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know - Zacks Investment Research
Novo Nordisk call volume above normal and directionally bullish - TipRanks
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):